The Genetics of Multiple Sclerosis

Miner, Annalise; Dastgheyb, Neda; Palomino, Miryam; Graves, Jennifer

doi:10.1007/978-3-030-61883-4_11

Cited by 1 publication

(1 citation statement)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple sclerosis (MS) is characterised by progressive demyelination and neuronal degradation along with systemic neuroinflammation in the CNS, present throughout the whole disease process, activating both the adaptive and innate immune system [ 37 ]. The etiology of MS is largely unknown; however, this disease has strong genetic and epigenetic components that are thought to play a role in disease onset and progression [ 37 ]. In MS, activated microglia are continually recruited into the CNS by the perpetual signaling of inflammatory cytokines and the presence of ROS and RNS [ 38 ].…”

Section: Ageing and Neurodegenerative Diseasesmentioning

confidence: 99%

Mushroom Natural Products in Neurodegenerative Disease Drug Discovery

Abitbol

Mallard

Tiralongo

et al. 2022

Cells

View full text Add to dashboard Cite

The variety of drugs available to treat neurodegenerative diseases is limited. Most of these drug’s efficacy is restricted by individual genetics and disease stages and usually do not prevent neurodegeneration acting long after irreversible damage has already occurred. Thus, drugs targeting the molecular mechanisms underlying subsequent neurodegeneration have the potential to negate symptom manifestation and subsequent neurodegeneration. Neuroinflammation is a common feature of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis, and is associated with the activation of the NLRP3 inflammasome, which in turn leads to neurodegeneration. Inflammasome activation and oligomerisation is suggested to be a major driver of disease progression occurring in microglia. With several natural products and natural product derivatives currently in clinical trials, mushrooms have been highlighted as a rich and largely untapped source of biologically active compounds in both in vitro and in vivo neurodegenerative disease models, partially supported by successful clinical trial evaluations. Additionally, novel high-throughput methods for the screening of natural product compound libraries are being developed to help accelerate the neurodegenerative disease drug discovery process, targeting neuroinflammation. However, the breadth of research relating to mushroom natural product high-throughput screening is limited, providing an exciting opportunity for further detailed investigations.

show abstract

Section: Ageing and Neurodegenerative Diseasesmentioning

confidence: 99%